MaaT033 capsule

DRUG2 trials

Sponsors

MaaT Pharma, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Chemotherapy EffectHematologic DiseasesNSCLC (Advanced Non-small Cell Lung Cancer)

Phase 1

Safety and Tolerability Evaluation of MaaT033

CompletedNCT04150393

MaaT PharmaChemotherapy Effect, Hematologic Diseases

Start: 2020-10-20End: 2021-12-13Updated: 2022-04-12

Phase 2

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

RecruitingNCT07001618

Gustave Roussy, Cancer Campus, Grand ParisNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2025-11-17End: 2032-09-01Target: 162Updated: 2026-04-03

Related Papers

Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial

Blood Advances2025-04-083 citations

Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients.

2021-05-2565 citations